A daily infectious disease news update
Hello and thank you for joining Contagion. I’m here with a brief on our latest infectious disease clinical coverage:
A study team supported by the Agency for Healthcare Research and Quality, sought to summarize evidence about the benefits and harms of hydroxychloroquine and chloroquine as treatments or prophylaxis of COVID-19. The study team ultimately concluded that evidence on the benefits and harms of using hydroxychloroquine or chloroquine to treat COVID-19 is very weak and conflicting, alongside a lack of empirical study on use as prophylaxis.
In other news, early links between heart disease and diabetes with coronavirus severity caused some to fear that ACE inhibitors and ARBs might worsen outcomes during the pandemic. A systematic review finds little evidence to back those fears.
And lastly, in an interview with our editorial director, Dr. Kelly Cawcutt, shared her thoughts on COVID's impact on health care, as well as why it's so important for clinicians to take breaks.
For more on these stories and the latest infectious disease news, visit contagionlive.com. Thanks for watching.